Cytotoxic T Lymphocytes , Na Qiao , Mao Zhang , Madhushree ... · fucosylation of selectin ligands in T cell homing and trafficking; however, to date, ex vivo. fucosylation has been
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-specific
Cytotoxic T Lymphocytes
Gheath Alatrash*1, Na Qiao2†, Mao Zhang1†, Madhushree Zope1, Alexander A.
Perakis1, Pariya Sukhumalchandra1, Anne V. Philips2, Haven R. Garber1, Celine
Kerros1, Lisa S. St. John1, Maria R. Khouri1, Hiep Khong3, Karen Clise-Dwyer1,
Leonard P. Miller4, Steve Wolpe4, Willem W. Overwijk3, Jeffrey J. Molldrem1,
Qing Ma1, Elizabeth J. Shpall1, Elizabeth A. Mittendorf*5
Affiliations:
Departments of 1Stem Cell Transplantation and Cellular Therapy, 2Breast
Surgical Oncology, 3Melanoma Medical Oncology, The University of Texas MD
Anderson Cancer Center, Houston, TX, USA; 4Targazyme Inc., Carlsbad, CA,
USA; 5Surgical Oncology, Dana-Farber/Brigham and Women’s Cancer Center,
Boston, MA, USA
†Contributed equally to this manuscript
Running Title: Fucosylation enhances T cell anti-tumor efficacy
Key Words: Immunotherapy, T cells, Breast Cancer, Leukemia
Financial Support: This work was supported by a grant from the Leukemia
Research Foundation (G.A.); Leukemia & Lymphoma Society (G.A.); Nancy
Owens Memorial Foundation and Pink Ribbons Project (EAM) and Cancer
Center Support Grant NCI #CA16672. E.A. Mittendorf is an R. Lee Clark Fellow
at The University of Texas MD Anderson Cancer Center, supported by the
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
1. Sackstein R, Schatton T, Barthel SR. T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy. Lab Invest 2017;97(6):669-97 doi 10.1038/labinvest.2017.25.
2. Abastado JP. The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor. Cancer Res 2012;72(9):2159-61 doi 10.1158/0008-5472.CAN-11-3538.
3. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nature reviews Immunology 2007;7(9):678-89 doi 10.1038/nri2156.
4. Kurachi M, Kurachi J, Suenaga F, Tsukui T, Abe J, Ueha S, et al. Chemokine receptor CXCR3 facilitates CD8(+) T cell differentiation into short-lived effector cells leading to memory degeneration. The Journal of experimental medicine 2011;208(8):1605-20 doi 10.1084/jem.20102101.
5. Bromley SK, Mempel TR, Luster AD. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol 2008;9(9):970-80 doi 10.1038/ni.f.213.
6. Sperandio M, Gleissner CA, Ley K. Glycosylation in immune cell trafficking. Immunol Rev 2009;230(1):97-113 doi 10.1111/j.1600-065X.2009.00795.x.
7. Zarbock A, Ley K, McEver RP, Hidalgo A. Leukocyte ligands for endothelial selectins: specialized glycoconjugates that mediate rolling and signaling under flow. Blood 2011;118(26):6743-51 doi 10.1182/blood-2011-07-343566.
8. Homeister JW, Thall AD, Petryniak B, Maly P, Rogers CE, Smith PL, et al. The alpha(1,3)fucosyltransferases FucT-IV and FucT-VII exert collaborative control over selectin-dependent leukocyte recruitment and lymphocyte homing. Immunity 2001;15(1):115-26.
9. Arbones ML, Ord DC, Ley K, Ratech H, Maynard-Curry C, Otten G, et al. Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice. Immunity 1994;1(4):247-60.
10. Xu J, Grewal IS, Geba GP, Flavell RA. Impaired primary T cell responses in L-selectin-deficient mice. J Exp Med 1996;183(2):589-98.
11. Sarkar AK, Rostand KS, Jain RK, Matta KL, Esko JD. Fucosylation of disaccharide precursors of sialyl LewisX inhibit selectin-mediated cell adhesion. J Biol Chem 1997;272(41):25608-16.
12. Tu L, Delahunty MD, Ding H, Luscinskas FW, Tedder TF. The cutaneous lymphocyte antigen is an essential component of the L-selectin ligand induced on human vascular endothelial cells. J Exp Med 1999;189(2):241-52.
13. Smithson G, Rogers CE, Smith PL, Scheidegger EP, Petryniak B, Myers JT, et al. Fuc-TVII is required for T helper 1 and T cytotoxic 1 lymphocyte selectin ligand expression and recruitment in inflammation, and together with Fuc-TIV regulates naive T cell trafficking to lymph nodes. J Exp Med 2001;194(5):601-14.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
14. Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997;389(6654):978-81 doi 10.1038/40166.
15. Maly P, Thall A, Petryniak B, Rogers CE, Smith PL, Marks RM, et al. The alpha(1,3)fucosyltransferase Fuc-TVII controls leukocyte trafficking through an essential role in L-, E-, and P-selectin ligand biosynthesis. Cell 1996;86(4):643-53.
16. Smith PL, Gersten KM, Petryniak B, Kelly RJ, Rogers C, Natsuka Y, et al. Expression of the alpha(1,3)fucosyltransferase Fuc-TVII in lymphoid aggregate high endothelial venules correlates with expression of L-selectin ligands. J Biol Chem 1996;271(14):8250-9.
17. Bradley LM, Watson SR, Swain SL. Entry of naive CD4 T cells into peripheral lymph nodes requires L-selectin. J Exp Med 1994;180(6):2401-6.
18. Stark FC, Gurnani K, Sad S, Krishnan L. Lack of functional selectin ligand interactions compromises long term tumor protection by CD8+ T cells. PLoS One 2012;7(2):e32211 doi 10.1371/journal.pone.0032211.
19. Etzioni A, Frydman M, Pollack S, Avidor I, Phillips ML, Paulson JC, et al. Brief report: recurrent severe infections caused by a novel leukocyte adhesion deficiency. N Engl J Med 1992;327(25):1789-92 doi 10.1056/NEJM199212173272505.
20. Frydman M, Etzioni A, Eidlitz-Markus T, Avidor I, Varsano I, Shechter Y, et al. Rambam-Hasharon syndrome of psychomotor retardation, short stature, defective neutrophil motility, and Bombay phenotype. Am J Med Genet 1992;44(3):297-302 doi 10.1002/ajmg.1320440307.
21. Schmidt S, Moser M, Sperandio M. The molecular basis of leukocyte recruitment and its deficiencies. Mol Immunol 2013;55(1):49-58 doi 10.1016/j.molimm.2012.11.006.
22. Robinson SN, Thomas MW, Simmons PJ, Lu J, Yang H, Parmar S, et al. Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. Cytotherapy 2014;16(1):84-9 doi 10.1016/j.jcyt.2013.07.003.
23. Robinson SN, Simmons PJ, Thomas MW, Brouard N, Javni JA, Trilok S, et al. Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rgamma(null) mice. Exp Hematol 2012;40(6):445-56 doi 10.1016/j.exphem.2012.01.015.
24. Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, et al. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 2015;125(19):2885-92 doi 10.1182/blood-2015-01-607366.
25. Parmar S, Liu X, Najjar A, Shah N, Yang H, Yvon E, et al. Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo. Blood 2015;125(9):1502-6 doi 10.1182/blood-2014-10-603449.
26. Sergeeva A, Alatrash G, He H, Ruisaard K, Lu S, Wygant J, et al. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood 2011;117(16):4262-72 doi 10.1182/blood-2010-07-299248.
27. Zhang M, Sukhumalchandra P, Enyenihi AA, St John LS, Hunsucker SA, Mittendorf EA, et al. A Novel HLA-A*0201 Restricted Peptide Derived from Cathepsin G Is an Effective Immunotherapeutic Target in Acute Myeloid Leukemia. Clin Cancer Res 2013;19(1):247-57 doi 10.1158/1078-0432.CCR-12-2753.
28. Alatrash G, Garber HR, Zhang M, Sukhumalchandra P, Qiu Y, Jakher H, et al. Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. Leukemia 2017;31(1):234-7 doi 10.1038/leu.2016.249.
29. Qazilbash MH, Wieder E, Thall PF, Wang X, Rios R, Lu S, et al. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia 2017;31(3):697-704 doi 10.1038/leu.2016.254.
30. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000;6(9):1018-23.
31. Mittendorf EA, Clifton GT, Holmes JP, Clive KS, Patil R, Benavides LC, et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2012;118(10):2594-602 doi 10.1002/cncr.26574.
32. Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2008;14(3):797-803 doi 14/3/797 [pii]
10.1158/1078-0432.CCR-07-1448. 33. Khong H, Volmari A, Sharma M, Dai Z, Imo CS, Hailemichael Y, et al.
Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8(+) T Cell Response. J Immunol 2018;200(10):3464-74 doi 10.4049/jimmunol.1700467.
34. Rodriguez-Cruz TG, Liu S, Khalili JS, Whittington M, Zhang M, Overwijk W, et al. Natural splice variant of MHC class I cytoplasmic tail enhances dendritic cell-induced CD8 T-cell responses and boosts anti-tumor immunity. PLoS One 2011;6(8):e22939 doi 10.1371/journal.pone.0022939.
35. Porcelli S, Morita CT, Brenner MB. CD1b restricts the response of human CD4-8- T lymphocytes to a microbial antigen. Nature 1992;360(6404):593-7 doi 10.1038/360593a0.
36. Alatrash G, Mittendorf EA, Sergeeva A, Sukhumalchandra P, Qiao N, Zhang M, et al. Broad Cross-Presentation of the Hematopoietically Derived PR1 Antigen on Solid Tumors Leads to Susceptibility to PR1-Targeted Immunotherapy. J Immunol 2012;189(11):5476-84 doi 10.4049/jimmunol.1201221.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
37. Mittendorf EA, Alatrash G, Qiao N, Wu Y, Sukhumalchandra P, St John LS, et al. Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune response. Cancer Res 2012;72(13):3153-62 doi 10.1158/0008-5472.CAN-11-4135.
38. Shultz LD, Schweitzer PA, Christianson SW, Gott B, Schweitzer IB, Tennent B, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995;154(1):180-91.
39. Ma Q, Wang C, Jones D, Quintanilla KE, Li D, Wang Y, et al. Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model. Cytotherapy 2010;12(8):1056-62 doi 10.3109/14653249.2010.506506.
40. Sergeeva A, He H, Ruisaard K, St John L, Alatrash G, Clise-Dwyer K, et al. Activity of 8F4, a T-cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo. Leukemia 2016;30(7):1475-84 doi 10.1038/leu.2016.57.
41. Campanelli AP, Martins GA, Souto JT, Pereira MS, Livonesi MC, Martinez R, et al. Fas-Fas ligand (CD95-CD95L) and cytotoxic T lymphocyte antigen-4 engagement mediate T cell unresponsiveness in patients with paracoccidioidomycosis. J Infect Dis 2003;187(9):1496-505 doi 10.1086/374646.
42. He JS, Ostergaard HL. CTLs contain and use intracellular stores of FasL distinct from cytolytic granules. J Immunol 2007;179(4):2339-48.
43. Pockaj BA, Sherry RM, Wei JP, Yannelli JR, Carter CS, Leitman SF, et al. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 1994;73(6):1731-7.
44. Garetto S, Sardi C, Martini E, Roselli G, Morone D, Angioni R, et al. Tailored chemokine receptor modification improves homing of adoptive therapy T cells in a spontaneous tumor model. Oncotarget 2016;7(28):43010-26 doi 10.18632/oncotarget.9280.
45. Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM, et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother 2010;33(8):780-8 doi 10.1097/CJI.0b013e3181ee6675.
46. Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, Zhang M, et al. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res 2010;16(22):5458-68 doi 10.1158/1078-0432.CCR-10-0712.
47. Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean MC, Validire P, Trautmann A, et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest 2012;122(3):899-910 doi 10.1172/JCI45817.
48. Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
redirected T lymphocytes. Nat Med 2015;21(5):524-9 doi 10.1038/nm.3833.
49. Calcinotto A, Grioni M, Jachetti E, Curnis F, Mondino A, Parmiani G, et al. Targeting TNF-alpha to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J Immunol 2012;188(6):2687-94 doi 10.4049/jimmunol.1101877.
50. Dirkx AE, oude Egbrink MG, Castermans K, van der Schaft DW, Thijssen VL, Dings RP, et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J 2006;20(6):621-30 doi 10.1096/fj.05-4493com.
51. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10(9):909-15 doi 10.1038/nm1100.
52. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005;115(6):1616-26 doi 10.1172/JCI24480.
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527
Published OnlineFirst January 15, 2019.Clin Cancer Res Gheath Alatrash, Na Qiao, Mao Zhang, et al. antigen-specific cytotoxic T lymphocytesFucosylation enhances the efficacy of adoptively transferred
Updated version
10.1158/1078-0432.CCR-18-1527doi:
Access the most recent version of this article at:
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://clincancerres.aacrjournals.org/content/early/2019/01/15/1078-0432.CCR-18-1527To request permission to re-use all or part of this article, use this link
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 15, 2019; DOI: 10.1158/1078-0432.CCR-18-1527